Phase I/II trial of a low-emetic combination of S-1 plus docetaxel (DTX) for advanced non-small cell lung cancer (NSCLC).Kenichiro Komiyama, Keigo Kobayashi, Shohei Minezaki et al.|Journal of Clinical Oncology|2011Cited by 0